hVIVO plc (LON:HVO – Get Free Report) traded down 6.8% during trading on Friday . The stock traded as low as GBX 19 ($0.24) and last traded at GBX 19.10 ($0.24). 2,518,262 shares were traded during mid-day trading, a decline of 26% from the average session volume of 3,389,765 shares. The stock had previously closed at GBX 20.50 ($0.25).
hVIVO Stock Performance
The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The company has a market capitalization of £129.95 million, a price-to-earnings ratio of 636.67 and a beta of 0.97. The business has a fifty day moving average price of GBX 23.20 and a 200 day moving average price of GBX 26.66.
About hVIVO
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Recommended Stories
- Five stocks we like better than hVIVO
- What Investors Need to Know About Upcoming IPOs
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
- What does consumer price index measure?
- Nebius Group: The Rising Star in AI Infrastructure
- Investing in Construction Stocks
- MarketBeat Week in Review – 12/30 – 1/03
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
